natgillin/translations-raw huggingface dataset:
Paragraph 14. The CD3 -binding molecule or diabody of paragraph 13, wherein said molecule or diabody is capable of immunospecifically binding to CD3 and to a molecule involved in said T cell - B cell association and said molecule involved in said T cell - B cell association is selected from the group consisting of CD 19, CD20, CD22, CD23, CD27, CD32B, CD38, CD40, CD79a, CD79b, CD80, CD86, LFA-I, LFA-3 and CFA-I. 
CD3-vezujuća molekula prema patentnom zahtjevu 11, naznačena time što navedena molekula je sposobna za imunospecifično vezanje za CD3 i za antigen, receptor ili receptor ligand na staničnoj površini, pri čemu navedeni antigen, receptor ili receptor ligand na staničnoj površini je molekula uključena u vezu T stanice - B stanice, pri čemu je navedena molekula uključen u navedenu vezu T stanice - B stanice izabran iz grupe koja se sastoji od CD19, CD20, CD22, CD23, CD27, CD32B, CD38, CD40, CD79a, CD79b, CD$0, CD86, LFA-I, LFA-3 i CFA-I.
Compound according to claim 1, wherein the substituents of the pair (R1, R5) are identical and the substituents of the pair (R2, R4) are identical. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da su supstituenti para (R1, R5) te supstituenti para (R2, R4) istovjetni.
is selected from the group consisting 
Ri je odabran iz skupine koja sadrži
A compound for use according to claim 1, wherein anti-HER2 Ab is an anti-HER2 antibody or antibody fragment, n is 0-1, m represents an average DAR of from 1 to 4, R1 is selected from y is 1-16, and R2 is selected from 
HER2 IHC 2+ ili 1+. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što anti-HER2 Ab je protutijelo ili fragment protutijela protiv HER2, nje 0-1, m predstavlja prosječni DAR od I do 4,
A process for producing and increasing yields of a polypeptide heterologous to E. coli comprising (a) culturing E. coli cells comprising nucleic acid encoding the polypeptide in a culture medium while feeding to the culture medium a transportable organophosphate that is selected from the group consisting of alpha-glycerophosphate, beta-glycerophosphate, glycerol-3-phosphate, and a mixture of glycerol-2-phosphate and glycerol-3-phosphate, such that the nucleic acid is expressed, and (b) recovering the polypeptide from the cells, so that the yields of the polypeptide are increased, wherein an inorganic phosphate is added to the culture medium during the culturing step. 
Postupak za proizvodnju i povećanje učinaka polipeptida heterolognih s £.coli, naznačen time, da obuhvaća (a) kultiviranje £. coli stanica koje sadrže nukleinsku kiselinu koja kodira polipeptid u mediju za kultiviranje, dok se medij za kultiviranje puni prenosivim organofosfatom odabranim iz skupine koju čine alfa-glicerofosfat, beta-glicerofosfat, glicerin-3-fosfat, i mješavina glicerin-2-fosfata i glicerin-3-fosfata, tako da se vrši ekspresija nukleinske kiseline, i b) obnavljanje polipeptida iz stanica, tako da se učinci polipeptida povećavaju, pri čemu se dodaje anorganski fosfat u medij za kultiviranje za vrijeme koraka kultiviranja. vonan
It has been shown in practice that, in view of the dimensions in the micrometer range, the choice of filling medium for the groove structures 4 results in a filling medium which can advantageously be used in liquid form for filling the groove structures 4 . 
Å to se tiče dimenzija u mikrometarskom području, u praksi se je pokazalo da izbor punila za brazdaste strukture 4 ima za posljedicu punilo koje se može povoljno upotrijebiti za punjenje brazdastih struktura 4 u tekućem obliku.
Method according to any of the claims 1, wherein the aqueous solution comprising a dissolved salt of Micafungin and the aqueous solution in step b) of the present method comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 4, naznačen time da vodena otopina koja sadrži otopljenu sol Micafungina u koraku a) sadrži organsko otapalo koje se miješa s vodom u rasponu od 10 % v/v.
a first step comprising adjusting the pH value of a solution comprising FVIII to a pH value of about 6.0, wherein the initial concentration of FVIII is about 1 mg/ml; 
Postupak prema zahtjevu 10, pri čemu je početna koncentracija terapeutskog proteina u prvom koraku oko 1 mg/ml i pH je oko 6.0;
wherein layer 2 is sandwiched between layers 1 and 3. 
PBAT, pri čemu je sloj 2 postavljen poput sendviča između slojeva 1 13.
15 and 16 respectively and that binds to domain II of HER2, and acidic variants of that main species HER2 antibody including a disulfide reduced variant and/or a non-reducible variant, wherein the main species HER2 antibody is the antibody amino acid sequence structure in the composition which is the quantitatively predominant antibody molecule in the composition and the main species HER2 antibody and the acidic variants are all intact antibodies, and (2) evaluating the acidic variants in the composition, and confirming that the amount thereof is less than about 25%. 
SEQ ID NO: 16, te se veže na domenu II od protutijela HER2, kao i kiselinske varijante od tog glavnog roda protutijela HER2, uključujući varijantu s redukcijom disulfida i/ili varijantu koja se ne može reducirati, pri čemu je glavni rod protutijela HER2, struktura aminokiselinske sekvence protutijela u sastavu, koja je kvantitativno nadmoćna molekula protutijela u sastavu, dok su svi 1 glavni rod protutijela HER2 1 kiselinske varijante, netaknuta protutijela, 1 (2) procjenjivanje kiselinskih varijanti sastava, te potvrđivanje da njihova količina iznosi manje od oko 25%.
The method according to claim 1, further comprising receiving a status of the handover request from the target cell with the highest weighted average of the RSRP. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u primanju stanja zahtjeva za prelazak 1z ciljane ćelije s najvišim ponderiranim prosjekom RSRP vrijednosti.
A CD19xCD3 bispecific single chain antibody construct for use in a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL) in a pediatric ALL patient, wherein said pediatric ALL is refractory to chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT). 
HR P20191715T1 PATENTNI ZAHTJEVI CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca za uporabu u postupku liječenja, poboljšanja ili uklanjanja dječje akutne limfoblastične leukemije (ALL) kod pedijatrijskog ALL pacijenta, naznačen time što navedena dječja ALL je refraktorna prema kemoterapiji ili alogenoj transplantaciji hematopoetskih matičnih stanica (HSCT).
The C-48 carton is placed within a chamber that maintains the relative processing humidity at 60% and the ambient processing temperature at 60° C. After a period of 5 to 9 days the temperature of the tobacco material reaches a temperature of about 60° C. and then continues to rise, to reach up a temperature of at least 5° C. above the ambient processing temperature after 7 to 13 days. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što temperatura duhanskog materijala dostiže drugu temperaturu koja je viša od okolišne temperature obrade, gdje druga temperatura može biti najmanje 2 "C viša od okolišne temperature obrade, i/ili gdje se drugu temperaturu može dostići unutar 7 do 13 dana.
According to some embodiments of the present invention, the fiber cement product may be a fiber cement plate having at least one surface comprising at least one groove. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što vlaknasti cementni proizvod je ploča od vlaknastog cementa koja ima najmanje jednu profiliranu površinu koja sadrži najmanje jedan žlijeb.
The device of claims 1-4 wherein the device reduces the patient's demand for systemic analgesia. 
Naprava iz patentnih zahtjeva 1-4, pri čemu naprava umanjuje pacijentovu potrebu za sustavnom analgezijom.
The rodent cell of claim 11, wherein T cell does not express a functional endogenous rodent CD8 co-receptor from its endogenous CD8 locus. The rodent cell of claim 11 or claim 12, wherein the T cell does not express CD4. A genetically modified rodent cell comprising a nucleic acid sequence encoding a chimeric human/rodent CD8a polypeptide and a nucleic acid sequence encoding a chimeric human/rodent CD8B polypeptide, wherein the chimeric human/rodent CD8a comprises at least an MHC I binding domain of a human CD8a polypeptide and at least transmembrane and cytoplasmic domains of a rodent CD8a polypeptide, wherein the chimeric human/rodent CD8B polypeptide comprises at least an MHC I binding domain of a human CD8B polypeptide and at least transmembrane and cytoplasmic domains of a rodent CD8B polypeptide, wherein the cell is an embryonic stem cell. 
pri čemu kimerni ljudski/glodarski CD8a polipeptid obuhvaća najmanje jednu vezujuću domenu MHC I od ljudskog CD8a polipeptida i najmanje transmembranske i citoplazmatske domene od glodarskog CD8a polipeptida, pri čemu kimerni ljudski/glodarski CD8B polipeptid obuhvaća najmanje jednu vezujuću domenu MHC I od ljudskog CD8B polipeptida i najmanje transmembranske i citoplazmatske domene od glodarskog CD8B polipeptida, pri čemu humanizirani MHC I polipeptid obuhvaća domene a1, a2 i a3 od ljudskog MHC I polipeptida i transmembranske i citoplazmatske domene od glodarskog MHC I polipeptida, pri čemu glodavac eksprimira kimerni ljudski/glodarski CD8 protein koji obuhvaća polipeptide CD8a i CD8B i humanizirani MHC I polipeptid, i prema izboru ljudski ili humanizirani B2 mikroglobulin, te pritom kimerni ljudski/glodarski CD8 protein i humanizirani MHC I polipeptid međusobno djeluju.
An antibody of the invention may be a monoclonal antibody. 
Uporaba sukladno zahtjevu 1, pri čemu je protutijelo monoklonsko protutijelo.
is a methine group optionally substituted by a hydroxyl group or a C1-6alkyl group, Q3 is a single bond, and R1d and R1e are independently a hydrogen atom or a C1-6alkyl group; or 
je metin skupina po izboru supstituirana hidroksil skupinom ili nižom alkilnom skupinom, Q3 je jednostruka veza, i R1d i R1e su nezavisno atom vodika ili niža alkilna skupina;
Said A0 pin, then, is able to sample the voltage applied thereon, through the A/D converter, and consequently is able to measure indirectly the current fed to the load by means of the current transformer 300: unit 50 ensures the disconnection of the switch (relay) 20, in a similar manner to that already described, in case of a current flowing in conductor 14 exceeding a pre-established threshold, thereby guaranteeing a short-circuit protection. 
Spomenuti A0 pin je tada sposoban uzorkovati napon koji se nalazi na njemu preko A/D konvertera, i tako može posredno mjeriti struju koja teče u trošilo preko strujnog transformatora 300; jedinica 50 osigurava odspajanje sklopke (releja) 20, na sličan način kako je prije opisano, u slučaju da struja u vodiču 14 prekorači prije utvrđeni prag, i tako osiguravajući zaštitu od kratkog spoja. HR P20060438 T3
m is 1 or 2, in free or salt form and, where possible, in acid addition salt form, as a vanilloid antagonist. 
Rs je vodik ili hidroksi; i mjelili2, u slobodnom obliku ili u obliku soli, i, gdje je to moguće, u obliku kiselinske adicijske soli, kao vaniloid antagonista.
a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. 
prvi djelatni sastojak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do 12, i drugi djelatni sastojak odabran od sljedećih: osmotska sredstva, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminska sredstva, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvi i drugi djelatni sastojci mogu biti u istom ili u drugačijem farmaceutskom sastavu.
neighbouring carriers are coupled to each other by a coupler, 
- susjedni nosači su međusobno spojeni pomoću spojnice (9),
A compound shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof: 
1. < Spoj prikazan općom formulom (1), ili njegova farmaceutski prihvatljiva sol: pi
Turbidity measurements for SDS/IL-2 mixtures can be converted into absolute specific turbidity (t) values as follows: EPMATHMARKEREP where: 
Mjerenja zamućenosti za smjese SDS/IL-2 se mogu konvertirati u vrijednosti apsolutne specifične zamućenosti (T) kako slijedi:
The use of 29 or 31, wherein the pulmonary disorder is chronic obstructive pulmonary disease or asthma. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time, da je plućna bolest kronična opstruktivna bolest pluća ili astma.
The pharmaceutically acceptable transdermal composition of claim 1, wherein (i) the composition has about 1 to about 10 weight percent active agent; and/or (ii) the composition has about 1 to about 5 weight percent fatty alcohol; and/or (iii) the composition has about 0.25 to about 5 weight percent terpene; and/or (iv) the fatty alcohol is octanol, preferably 1-octanol; and/or the terpene is d-limonene. 
Farmaceutski prihvatljiv transdermalni sastav iz zahtjeva 1, naznačeno time da (1) sastav ima između otprilike 1 i otprilike 10 posto težine aktivnog sastojka; i/ili (11) sastav ima između otprilike 1 i otprilike 5 posto težine masnog alkohola; i/ili (111) sastav ima između otprilike 0,25 i otprilike 5 posto težine terpena; i/ili (iv) masni alkohol je oktanol, poželjno 1-oktanol; i/ili je terpen d-limonen.
In a seventh aspect, the present disclosure includes a compound of Formula (III), (IIIa), (IIIb) or (IIIc): 
Spoj iz patentnog zahtjeva 1 koji ima formulu (III), (IIIa), (IIIb) ili (IIIc): HR P20180641 T1
an isolated polynucleotide comprising a sequence encoding a light chain of an antibody having the amino acid sequence of SEQ ID NO:174 or 180; and 
izolirani polinukleotid koji sadrži slijed koji kodira laki lanac protutijela koji ima aminokiselinski slijed SEQ ID NO: 174 ili 180; i
Process for the manufacture of a polymer fiber comprising the steps of melt-spinning of a polymer and subsequent treatment of the fiber with ionizing radiation. 
Postupak proizvodnje polimernog vlakna u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koracima predenja polimera iz taline, uz naknadnu obradu ionizirajućim zračenjem.
Names given to chemical substances herein generally are either accepted chemical names, or are trade organization or regulatory agency approved names such as CTFA Adopted Names as listed in J. A. Wenninger et al., Eds., CTFA International Cosmetic Ingredient Dictionary, Eighth Ed., The Cosmetic, Toiletry and Fragrance Association, Washington, D.C., 2000 . 
Nazivi dani kemijskim tvarima ovdje općenito su bilo prihvaćeni kemijski nazivi, ili su odobreni nazivi od strane trgovačke organizacije ili regulatorne agencije, kao npr. CTFA prihvaćeni nazivi kao što su navedeni u J. A. Wenninger i sur., izd., CIFA International Cosmetic Ingredient Dictionary, osmo izd., The Cosmetic, Toiletry i Fragrance Association, Washington, D.C., 2000.
The sewing or looping head according to claim 1, characterized in that said cutting element (10) is scissor-shaped, 
Glava za šivanje ili pravljenje petlji u skladu s patentnim zahtjevom 1, naznačena time, da navedeni rezni element (10) ima oblik škara.
The organic solvent was evaporated and the residue was chromatographed with 2:3 EtOAc/Hexane to give 13.4 g (20.8 mmol, 83%) yellow solid. 
Organsko otapalo se otpari, a ostatak kromatografira, uz eluiranje 2:3 smjesom EtOAc/heksan kako bi se dobilo 13,4 g (20,8 mmol, 83 %) žute krutine.
determining an athwartship vertical cable heaving angle B, from the shortest radar distance AF, a projected horizontal distance AB between detector reference point A and the cable suspension point E, and a projected vertical distance BE between the detector reference point A and the cable suspension point E, and optionally wherein determining the athwartship vertical cable heaving angle B comprises solving an equation: EPMATHMARKEREP 
određivanje kuta vuče fB poprečno vertikalnog kabla, od najkraće udaljenosti AF radara, projicirane horizontalne udaljenosti AB između referentne točke A detektora i točke ovjesa E kabla, te projicirane vertikalne udaljenosti BE između referentne točke A detektora i točke ovjesa E kabla, i po izboru gdje određivanje kuta vuče BB poprečno vertikalnog kabla obuhvaća rješavanje jednadžbe:
WO97/03572 discloses a method of stabilising a microwave cookable or reheatable food material by impregnation of the product with a stabiliser composition comprising cellulose gum, modified starch, polydextrose, xanthan gum, egg albumen and pea starch. According to the present invention a method of manufacture of a food product comprises the steps of: wholly or partially impregnating a substrate with a stabiliser composition wherein the substrate comprises pieces of meat, poultry, fish vegetable, fruit or dairy foods; 
HR P20120599 T1 PATENTNI ZAHTJEVI Postupak za proizvodnju prehrambenog proizvoda koji se može mikrovalno ili termalno kuhati ili ponovo zagrijavati, pri čemu proizvod sadrži supstrat koji sadrži komade peradi, ribe, crvenog mesa, povrća, voća ili mliječnog proizvoda; postupak sadrži korake: nanošenja omotača od kompozicije vodenog omotača na supstrat; pri čemu, kompozicija vodenog omotača sadrži vodu i 0.1 do 5% smjese koja sadrži po suhoj težini slijedeće sastojke: celulozna guma
represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, a C1-C6 haloalkyl group, a carboxyl group, an optionally substituted C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkoxycarbonyl group, an optionally substituted cycloalkyl group, an optionally substituted cyclohexylalkylalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted heterocycloalkylalkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted heteroaryl group, an optionally substituted heteroarylalkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted alkenylalkyl group, an optionally substituted heterocycloalkenyl group, an optionally substituted heterocycloalkenylalkyl group, an optionally substituted C2-C6 alkynyl group, or an optionally substituted alkynylalkyl group, 
R* predstavlja atom vodika, atom halogena, cijano grupu, nitro grupu, C1-C6 haloalkil grupu, karboksil grupu, po izboru supstituiranu C1-C6 alkil grupu, C1I-C6 alkoksi grupu, C1-C6 alkoksikabonil grupu, po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloheksialkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu heteroarilalkil gupu, po izboru supstituiranu C2-C6 alkenil grupu, po izboru supstituiranu alkenilalkil grupu po izboru supstituiranu heterocikloalkenil grupu, po izboru supstituiranu heterocikloalkenilalkil grupu, po izboru supstituiranu C2-C6 alkinil grupu, po izboru supstituiranu alkinilalkil grupu,
C2-6 alkynyl, or a 5- or 6-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 substituents selected from 
(2) 5-člana ili 6-člana monociklička aromatska heterociklička skupina koja opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
A pharmaceutical composition as claimed in any one of claims 1 to 25 for use in a method for treating a pulmonary disease or disorder in a patient. 
Ko-suspenzija u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što je namijenjena upotrebi u liječenje pacijenta koji boluje od upalne ili opstruktivne plućne bolesti ili stanja.
A method as claimed in claim 1, wherein said trajectory is a circular trajectory in a radial plane through said longitudinal axis and said point. 
Bubanj koji se štiti u Patentnom zahtjevu 18 ili 19, naznačen time, da je navedena putanja (T) kružna putanja u radijalnoj ravnini koja prolazi kroz uzdužnu os (3) i navedenu točku (P).
calculating the percentage of brominated tyrosine in the glatiramer acetate. A process for preparing a pharmaceutical composition containing a mixture of polypeptides which do not all have the same amino acid sequence, where each polypeptides consists essentially of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a predetermined percentage of brominated tyrosine acceptable for inclusion in a pharmaceutical composition; which comprises obtaining a batch of a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of glutamic acid, alanine, tyrosine and lysine; 
Postupak za pripremanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da glatiramer acetat ima predodređeni postotak bromiranog tirozina, prihvatljivog za uključivanje u farmaceutski sastav, koji postupak sadrži dobivanje šarže glatiramer acetata; mjerenje postotka bromiranog tirozina šarže postupkom koji sadrži a) hidroliziranje šarže da se dobije hidrolizat; b) eluiranje hidrolizata preko kromatografske kolone;
The nucleotide or nucleoside analogue reverse transcriptase inhibitor, comprised in the silica particles of the depot formulation of the present invention is typically incorporated into the silica particles employing a continuous process within a tube reactor wherein said nucleotide or nucleoside analogue reverse transcriptase inhibitor and the silica sol are continuously fed as separate flows into and combined in said reactor, then continuously fed out of said tube reactor and into a continuous spray drying process with continuous particle separation by a cyclone separator. 
Depo formulacija u skladu sa patentnim zahtjevom 10 naznačena time da nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze, sadržan u česticama silike, je inkorporiran u česticama silike koristeći kontinuirani proces unutar cijevnog reaktora gdje se navedeni nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze i silika sol kontinuirano dopremaju kao odvojeni tokovi unutar i kombiniraju u navedenom reaktoru, zatim se kontinuirano odvode iz navedenog cijevnog reaktora i u proces kontinuiranog sušenja raspršivanjem sa neprekidnim odvajanjem čestica pomoću ciklonskog separatora.
The filtrate was treated with 10 % NaHCO3 and the precipitate formed was separated in the same manner, resulting in a second fraction of dimethyl ester 3 (2 g). 
Filtrat se tretira s 10 % NaHCO; 1 nastali precipitat se odvoji na isti način, rezultirajući drugom frakcijom dimetil estera 3 (2 g).
The first step in a process for preparing IL-2 for pharmaceutical use will generally be expression of the protein. 
Prvi stupanj u procesu za pripravljanje IL-2 za farmaceutsku uporabu će općenito biti ekspresija proteina.
Thus, coding units adjacent to the current coding unit and the previous coding unit of the current coding unit in the coding order in the maximum coding unit may be candidates. In this case, the above scan order may be changed to the following scan order; 1) the left coding unit of the current coding unit, 2) the above coding unit of the current coding unit, 3) the above left coding unit of the current coding unit and 4) the previous coding unit of the current coding unit. 
Uređaj prema zahtjevu 1, naznačen time što jedinica za kvantizaciju (130) određuje prosjek od dvije važeće veličine kvantizacijskog koraka od veličine koraka kvantizacije lijeve jedinice kodiranja trenutne jedinice kodiranja, veličina kvantizacijskog koraka gore navedene jedinice kodiranja trenutne jedinice za kodiranje 1 veličinu koraka kvantizacije prethodne jedinice kodiranja trenutne jedinice kodiranja kao prediktor veličine kvantizacijskog koraka i prenosi razliku između veličine koraka kvantizacije i prediktora veličine kvantizacijskog koraka u jedinici za entropijsko kodiranje (140).
4.8% by weight levodopa, 1.4% by weight carbidopa, 1% by weight Na-ascorbate, and 11%, 11.6%, 12.1 % or 12.7%, by weight arginine; 
(i) 4,8% masenog udjela levodopa, 1,4% masenog udjela karbidopa, 1% masenog udjela natrijevog askorbata, i 11%, 11,6%, 21,1% ili 12,7% masenog udjela arginina;